Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for Drug-Resistant lung cancer

NCT ID NCT03133546

Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combination delayed cancer growth better than osimertinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

155 people

The number who actually took part.

Started

May 2017

Finished

Feb 2024

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients (male/female) must be \>18 years of age. * Patients diagnosed with NSCLC, stage IIIb/IIIc (not amenable to radical therapy) or IVa/IVb according to 8th TNM classification, after progression following prior EGFR TKI therapy (erlotinib, gefitinib, dacomitinib or afatinib) as the most recent treatment regimen; * Pathological diagnosis of predominantly non-squamous NSCLC; * Maximum one line of previous platinum based chemotherapy; * Histological or cytological confirmation of EGFRm (exon 19 deletion or exon 21L858R); * Locally confirmed T790M mutation determined from biopsy (preferred) or on circulating tumour DNA, documented in tissue, plasma or serum after disease progression on the most recent treatment regimen; * Plasma, serum, and tumour (preferred) tissue or cytology (if biopsy was taken and FFPE tumor material is not yet fully depleted) after disease progression on the most recent EGFR TKI treatment available for central confirmation of T790M; * Measurable or evaluable disease according to RECIST 1.1; * Adequate haematological, renal and liver function; * World Health Organization (WHO) performance status 0-2. Exclusion Criteria: * Patients with mixed NSCLC with predominantly squamous cell cancer, or with any small cell lung cancer (SCLC) component; * Symptomatic or active central nervous system metastases, as indicated by progressive growth or increasing need of steroids. * Patients currently receiving medications or herbal supplements known to be potent CYP3A4 inducers; * Patients with any unresolved toxicities from prior therapy greater than CTCAE V 4.0 grade 1 (exception: alopecia \& grade 2, prior platinuma-therapy related neuropathy) * Previous treatment with osimertinib and/or bevacizumab;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer metastatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer metastatic

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Fund. Jimenez Diaz

    Madrid, Spain

  • Geneva University Hospital (HUG)

    Geneva, Switzerland

  • Hospital Arnau de Vilanova

    Valencia, Spain

  • Hospital General Alicante

    Alicante, Spain

  • Hospital General de Valencia

    Valencia, Spain

  • Hospital Puerta de Hierro

    Madrid, Spain

  • Hospital Sant Pau

    Barcelona, Spain

  • Hospital Teresa Herrara

    A Coruña, Spain

  • Hospital Virgen del Rocio

    Seville, Spain

  • Hospital de la Princesa

    Madrid, Spain

  • Hospital la Paz

    Madrid, Spain

  • ICO Badalona

    Barcelona, Spain

  • ICO Hospitalet

    Barcelona, Spain

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • Kantonsspital Winterthur

    Winterthur, Switzerland

  • Mid Western Cancer Centre

    Limerick, Ireland

  • National Cancer Centre

    Goyang, South Korea

  • National University Hospital

    Singapore, Singapore

  • OSI Bilbao Basurto

    Bilbao, Spain

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • St. James Hospital

    Dublin, Ireland

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • UniversitatSpital Zurich

    Zurich, Switzerland

  • VU University Medical Centre

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.